BRIEF published on 10/01/2026 at 10:05, 18 days 9 hours ago IOmx Therapeutics nomme Rüdiger Wolff au poste de directeur financier Directeur Financier Immuno-oncologie Leadership Financier IOmx Thérapeutique Rüdiger Wolff
BRIEF published on 10/01/2026 at 10:05, 18 days 9 hours ago IOmx Therapeutics Appoints Rüdiger Wolff as CFO Chief Financial Officer Immuno-oncology IOmx Therapeutics Finance Leadership Rüdiger Wolff
PRESS RELEASE published on 10/01/2026 at 10:00, 18 days 9 hours ago iOmx Therapeutics Appoints Rüdiger Wolff as Chief Financial Officer iOmx Therapeutics appoints Rüdiger Wolff as Chief Financial Officer, bringing extensive experience in life sciences and technology finance leadership roles Chief Financial Officer Life Sciences Finance IOmx Therapeutics Rüdiger Wolff
BRIEF published on 04/15/2025 at 10:05, 1 year 6 months ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
BRIEF published on 04/15/2025 at 10:05, 1 year 6 months ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
PRESS RELEASE published on 04/15/2025 at 10:00, 1 year 6 months ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year 10 months ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year 10 months ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year 10 months ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 2 years 1 month ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
Published on 10/19/2026 at 14:30, 5 hours ago Core Silver Intersects Copper Bearing VMS Mineralization at the Touleary Project
Published on 10/19/2026 at 14:00, 5 hours 30 minutes ago Four Nines Gold Intersects 80.1 Meters Averaging 1.08 g/t Gold in Expanding Lower Telegraph Corridor at Hayden Hill
Published on 10/19/2026 at 13:30, 6 hours ago Empress Announces Closing of Tongon Gold Stream Investment and Debt Financing
Published on 10/19/2026 at 13:30, 6 hours ago Mako Mining Announces Q3 2026 Production Results with Gold Recovered of 12,743 oz Au (Sales of 11,581 oz Au), and Positive Permitting Updates at Mt. Hamilton and San Albino
Published on 10/19/2026 at 13:01, 6 hours 29 minutes ago CoTec Holdings Corp. Notes HyProMag USA Deployment of Mobile Inserma System, Extending Hard Disk Drive Processing to Customer Sites Across the United States
Published on 10/19/2026 at 19:00, 30 minutes ago PATRIMOINE ET COMMERCE : Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 12/10/2026 au 16/10/2026
Published on 10/19/2026 at 18:05, 1 hour 25 minutes ago Cognizant and Google Cloud Expand Alliance to Accelerate Agentic Enterprise Transformation
Published on 10/19/2026 at 17:45, 1 hour 45 minutes ago VALBIOTIS SA: Valbiotis receives double “Best Pharma Product 2027” award for its ValbiotisPRO® Cholestérol and ValbiotisPRO® Santé Métabolique solutions
Published on 10/19/2026 at 17:45, 1 hour 45 minutes ago VALBIOTIS SA: Valbiotis doublement récompensé « Meilleur Produit Pharma 2027 » pour ses solutions ValbiotisPRO® Cholestérol et ValbiotisPRO® Santé Métabolique
Published on 10/19/2026 at 17:30, 2 hours ago GEVELOT S.A.: Déclaration hebdomadaire de rachat d'actions 19/10/2026
Published on 10/19/2026 at 19:00, 30 minutes ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 : Compte rendu et résultat des votes - Évolution de la gouvernance
Published on 10/19/2026 at 18:40, 50 minutes ago Reporting on share buyback transactions carried out between October 12 and October 13, 2026
Published on 10/19/2026 at 18:40, 50 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain les 12 et 13 octobre 2026
Published on 10/19/2026 at 18:00, 1 hour 30 minutes ago WHO Grants Emergency Use Listing for BIOFIRE® Global Fever Special Pathogens Panel, Expanding Access to Differential Diagnostics for the Ebola Response
Published on 10/19/2026 at 18:00, 1 hour 30 minutes ago L’OMS accorde une autorisation d’utilisation d’urgence au test BIOFIRE® Global Fever Special Pathogens, élargissant l’accès au diagnostic différentiel face à l’épidémie d’Ebola
